IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma 公布第 2 阶段中期数据,显示 IGC-AD1 已达到次要终点,并在第二周临床上显示阿尔茨海默氏症的激动情绪有所减轻
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma 公布第 2 阶段中期数据,显示 IGC-AD1 已达到次要终点,并在第二周临床上显示阿尔茨海默氏症的激动情绪有所减轻
使用浏览器的分享功能,分享给你的好友吧